495 related articles for article (PubMed ID: 33323237)
1. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial.
Benhamou PY; Franc S; Reznik Y; Thivolet C; Schaepelynck P; Renard E; Guerci B; Chaillous L; Lukas-Croisier C; Jeandidier N; Hanaire H; Borot S; Doron M; Jallon P; Xhaard I; Melki V; Meyer L; Delemer B; Guillouche M; Schoumacker-Ley L; Farret A; Raccah D; Lablanche S; Joubert M; Penfornis A; Charpentier G;
Lancet Digit Health; 2019 May; 1(1):e17-e25. PubMed ID: 33323237
[TBL] [Abstract][Full Text] [Related]
2. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136
[TBL] [Abstract][Full Text] [Related]
3. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
[TBL] [Abstract][Full Text] [Related]
4. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial.
Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J
Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750
[TBL] [Abstract][Full Text] [Related]
5. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.
Thabit H; Lubina-Solomon A; Stadler M; Leelarathna L; Walkinshaw E; Pernet A; Allen JM; Iqbal A; Choudhary P; Kumareswaran K; Nodale M; Nisbet C; Wilinska ME; Barnard KD; Dunger DB; Heller SR; Amiel SA; Evans ML; Hovorka R
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):701-9. PubMed ID: 24943065
[TBL] [Abstract][Full Text] [Related]
6. Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study.
Boughton CK; Hartnell S; Thabit H; Mubita WM; Draxlbauer K; Poettler T; Wilinska ME; Hood KK; Mader JK; Narendran P; Leelarathna L; Evans ML; Hovorka R
Lancet Healthy Longev; 2022 Mar; 3(3):e135-e142. PubMed ID: 35359882
[TBL] [Abstract][Full Text] [Related]
7. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
Bergenstal RM; Nimri R; Beck RW; Criego A; Laffel L; Schatz D; Battelino T; Danne T; Weinzimer SA; Sibayan J; Johnson ML; Bailey RJ; Calhoun P; Carlson A; Isganaitis E; Bello R; Albanese-O'Neill A; Dovc K; Biester T; Weyman K; Hood K; Phillip M;
Lancet; 2021 Jan; 397(10270):208-219. PubMed ID: 33453783
[TBL] [Abstract][Full Text] [Related]
8. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
[TBL] [Abstract][Full Text] [Related]
9. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial.
Daly AB; Boughton CK; Nwokolo M; Hartnell S; Wilinska ME; Cezar A; Evans ML; Hovorka R
Nat Med; 2023 Jan; 29(1):203-208. PubMed ID: 36631592
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
[TBL] [Abstract][Full Text] [Related]
11. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
[TBL] [Abstract][Full Text] [Related]
12. Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol.
Musolino G; Allen JM; Hartnell S; Wilinska ME; Tauschmann M; Boughton C; Campbell F; Denvir L; Trevelyan N; Wadwa P; DiMeglio L; Buckingham BA; Weinzimer S; Acerini CL; Hood K; Fox S; Kollman C; Sibayan J; Borgman S; Cheng P; Hovorka R
BMJ Open; 2019 Jun; 9(6):e027856. PubMed ID: 31164368
[TBL] [Abstract][Full Text] [Related]
13. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial.
Ware J; Boughton CK; Allen JM; Wilinska ME; Tauschmann M; Denvir L; Thankamony A; Campbell FM; Wadwa RP; Buckingham BA; Davis N; DiMeglio LA; Mauras N; Besser REJ; Ghatak A; Weinzimer SA; Hood KK; Fox DS; Kanapka L; Kollman C; Sibayan J; Beck RW; Hovorka R;
Lancet Digit Health; 2022 Apr; 4(4):e245-e255. PubMed ID: 35272971
[TBL] [Abstract][Full Text] [Related]
14. Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.
Kim JY; Jin SM; Kang ES; Kwak SH; Yang Y; Yoo JH; Bae JH; Moon JS; Jung CH; Bae JC; Suh S; Moon SJ; Song SO; Chon S; Kim JH
Diabetologia; 2024 Jul; 67(7):1235-1244. PubMed ID: 38634887
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
[TBL] [Abstract][Full Text] [Related]
16. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.
Benhalima K; Beunen K; Van Wilder N; Ballaux D; Vanhaverbeke G; Taes Y; Aers XP; Nobels F; Marlier J; Lee D; Cuypers J; Preumont V; Siegelaar SE; Painter RC; Laenen A; Gillard P; Mathieu C
Lancet Diabetes Endocrinol; 2024 Jun; 12(6):390-403. PubMed ID: 38697182
[TBL] [Abstract][Full Text] [Related]
17. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709
[TBL] [Abstract][Full Text] [Related]
18. Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol.
McAuley SA; de Bock MI; Sundararajan V; Lee MH; Paldus B; Ambler GR; Bach LA; Burt MG; Cameron FJ; Clarke PM; Cohen ND; Colman PG; Davis EA; Fairchild JM; Hendrieckx C; Holmes-Walker DJ; Horsburgh JC; Jenkins AJ; Kaye J; Keech AC; King BR; Kumareswaran K; MacIsaac RJ; McCallum RW; Nicholas JA; Sims C; Speight J; Stranks SN; Trawley S; Ward GM; Vogrin S; Jones TW; O'Neal DN
BMJ Open; 2018 Jun; 8(6):e020274. PubMed ID: 29886443
[TBL] [Abstract][Full Text] [Related]
19. Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol.
Leelarathna L; Dellweg S; Mader JK; Barnard K; Benesch C; Ellmerer M; Heinemann L; Kojzar H; Thabit H; Wilinska ME; Wysocki T; Pieber TR; Arnolds S; Evans ML; Hovorka R;
BMJ Open; 2014 Sep; 4(9):e006075. PubMed ID: 25186158
[TBL] [Abstract][Full Text] [Related]
20. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]